Trial on Treatment Options for Major Depressive Disorder with TRD Initiated
A multi-site trial is comparing aripiprazole augmentation, rTMS augmentation, and switching to venlafaxine XR or Duloxetine for TRD patients.
Asset / Drug
Drug and asset intelligence for aripiprazole with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.